World Diabetes Day: From Awareness to Prevention

November 14, World Diabetes Day, provides an important opportunity to raise awareness about a chronic condition that affects an increasing number of people worldwide and represents a major public health challenge.

According to the 11th edition of the International Diabetes Federation (IDF) Diabetes Atlas (2025), approximately 589 million adults aged 20–79 were living with diabetes in 2024, representing nearly 1 in 9 adults. More than 250 million people were unaware that they had the condition, while the number of people living with diabetes is projected to reach 853 million by 2050. Global healthcare expenditure related to diabetes exceeded USD 1 trillion in 2024.

Type 2 diabetes, which accounts for more than 90% of all diabetes cases, is associated with obesity, physical inactivity, genetic predisposition, and other metabolic factors. It often develops without noticeable symptoms and can increase the risk of cardiovascular disease, heart failure, kidney damage, diabetic retinopathy, and neuropathy.

The encouraging news is that type 2 diabetes can, in many cases, be prevented or significantly delayed. Following a Mediterranean diet, engaging in regular physical activity—with a target of at least 150 minutes of moderate-intensity exercise per week—and maintaining a healthy body weight are key pillars of prevention. Even a 5–7% reduction in initial body weight can substantially improve metabolic parameters and reduce the risk of progression from prediabetes to type 2 diabetes.

Early diagnosis is equally important. Diabetes screening is generally recommended from the age of 35, although earlier screening may be necessary for individuals who are overweight and have additional risk factors, such as a family history of diabetes, hypertension, or a history of gestational diabetes. Fasting plasma glucose and glycated hemoglobin (HbA1c) are among the primary diagnostic tests used, with further testing performed when clinically indicated.

At the same time, diabetes treatment has advanced significantly. Metformin remains a reliable treatment option, but medication is now selected through an individualized approach that considers not only blood glucose control but also body weight, cardiovascular health, and kidney function. GLP-1 receptor agonists, such as semaglutide, and the dual GIP/GLP-1 receptor agonist tirzepatide offer substantial reductions in blood glucose levels and body weight in appropriately selected patients.

Furthermore, SGLT2 inhibitors, such as empagliflozin and dapagliflozin, are particularly important because, in specific patient populations, they provide cardiovascular and renal protection beyond their glucose-lowering effects. Current clinical guidelines increasingly emphasize the early use of treatments with proven benefits for target organs when clinically indicated.

Technology also plays an important role in modern diabetes management. Continuous glucose monitoring (CGM) systems provide a better understanding of blood glucose fluctuations and can facilitate treatment adjustments. For certain individuals requiring insulin therapy, automated insulin delivery systems offer additional opportunities for safer and more effective glucose management.

However, no medication or technological intervention can replace comprehensive care, which includes a balanced diet, regular physical activity, smoking cessation, blood pressure and cholesterol management, and consistent medical follow-up.

World Diabetes Day reminds us that awareness, prevention, and personalized treatment can make a meaningful difference in the progression of diabetes and the quality of life of people living with the condition.

Maria Tsiogka, MD, PhD

Endocrinologist, Medical Associate, Euromedica Egkefalos Chalandriou

Scroll to Top